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Background: The aim of this study was to analyze the clinicopathological characteristics and the prognostic factors
for survival and recurrence of young patients who had undergone hepatectomy for hepatocellular carcinoma.
Methods: Between 1990 and 2010, 31 patients aged 40 years or younger (younger patient group) among 811
consecutive patients with hepatocellular carcinoma who had undergone primary hepatectomy were analyzed with
regard to patient factors, including liver function, tumor factors and operative factors. The clinicopathological
characteristics of the younger patients were compared with those of patients over the age of 40 (older patient
group). Then the prognostic factors of the younger patients were analyzed. Continuous variables were expressed as
the means ± standard deviation and compared using the χ2 test for categorical variables. Overall survival and
recurrence-free survival rates were determined by the Kaplan-Meier method and analyzed by the log-rank test. The
Cox proportional hazards model was used for multivariate analysis.
Results: In the younger patients, the rates of HBs-antigen-positivity, high alpha-fetoprotein, portal invasion,
intrahepatic metastasis, large tumors, low indocyanin green retention rate at 15 minutes, and anatomical resection
were significantly higher than the same measures in the older patients. The five-year overall survival rate of the
young patients was 49.6%. The prognostic factors of survival were HCV-antibody-positivity and low albumin status.
Prognostic factors of recurrence were multiple tumors and the presence of portal invasion.
Conclusions: In younger patients, survival appeared to be primarily affected by liver function, while recurrence was
affected by tumor factors. Young patients with hepatocellular carcinoma should be aggressively treated with
hepatectomy due to their good pre-surgical liver function.
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Liver cancers are malignant tumors and are the third lead-
ing cause of cancer-related death; they are responsible for
approximately 700,000 deaths per year [1]. Hepatocellular
carcinoma (HCC) has a poor prognosis and accounts for
70 to 85% of primary liver cancers [2]. Generally, there are
few opportunities for discovery of malignant tumors in
younger patients, and thus they tend to present with a
highly advanced malignancy at the time of diagnosis;* Correspondence: shingoshimada1979@true.ocn.ne.jp
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reproduction in any medium, provided the ornonetheless, younger patients can expect long-term sur-
vival. The definition of what constitutes a “young patient”
differs between studies [3-12]. HCC is fairly rare in youn-
ger individuals, with an occurrence rate of only 0.6 to 2.7%
in those under 40 years of age, according to Japanese re-
ports [12-14]. In Asia and Africa, which are areas with
prevalent hepatitis B virus (HBV), the frequency of HCC is
higher than in Japan [4,8,9,11,15]; however, there are still
few reports on independent prognostic factors in young
patients with HCC.
In this study, we examined the prognostic clinicopath-
ological features, as well as the prognostic factors foral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.













HBs-Ag positive 26 (84%) 321 (41%) <0.0001
HCV-Ab positive 1 (3%) 310 (40%) <0.0001
Biochemical Factors
Albumin ≥4.0 g/l 17 (55%) 411 (53%) NS
Total bilirubin ≥0.8 mg/dl 17 (55%) 379 (49%) NS
ICGR15 ≥15 3 (10%) 360 (46%) 0.0001
AFP ≥200 ng/ml 16 (52%) 210 (27%) 0.0026
Tumor Factors
Number of tumors: 1 20 (65%) 522 (67%) NS
2 to 3 6 (19%) 183 (23%)
≥4 5 (16%) 75 (10%)
Maximum size of tumors: <2 cm 4 (12%) 83 (11%) 0.0074
≥2 cm, <5 cm 7 (23%) 395 (50%)
≥5 cm 20 (65%) 303 (39%)
Macroscopic classification: simple
nodular type
10 (32%) 408 (52%) NS
simple nodular type with
extranodular grow
10 (32%) 222 (28%)
confluent multinodular type 8 (26%) 122 (16%)
infiltrative type 0 (0%) 6 (1%)
others 3 (10%) 22 (3%)
Distant metastasis positive 2 (6%) 18 (2%) NS
Surgical Factors
Anatomical resection 29 (94%) 525 (67%) 0.0021
Histological Factors
Differentiation: well 3 (10%) 114 (15%) NS
moderate 13 (42%) 430 (55%)
poor 14 (45%) 209 (27%)
others 1 (3%) 27 (3%)
vp:vp0 14 (45%) 569 (73%) 0.0026
vp1 9 (29%) 125 (16%)
vp2,3,4 8 (26%) 86 (11%)
im 16 (52%) 264 (34%) 0.0413
cirrhosis 9 (29%) 287 (37%) NS
AFP, alpha-fetoprotein; HBs-Ag, HBs-antigen; HCV-Ab, HCV-antibody;
ICGR15, indocyanin green retention rate at 15 minutes; im, microscopic
intrahepatic metastasis; NS, non-significant; vp0, no tumor thrombus in
the portal vein; vpl, tumor thrombus distal to the second branches of the
portal vein; vp2, tumor thrombus in the second branches of the portal
vein; vp3, tumor thrombus in the first branch of the portal vein; vp4,
tumor thrombus extension to the trunk or the opposite side branch of the
portal vein.
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who had undergone hepatectomy.
Methods
Between January 1990 and May 2010, 811 consecutive
patients with HCC underwent primary liver resection at
the Gastroenterological Surgery I unit of Hokkaido Uni-
versity Hospital in Sapporo, Japan. Of these patients, 31
patients (3.8%) were 40 years old or younger, while 780
patients (96.2%) were over 40 years of age. For group
stratification, the former patients were defined as the
younger patient group, and the latter as the older patient
group. This study was approved by the Hokkaido Uni-
versity Hospital Voluntary Clinical Study Committee
and was performed according to the Helsinki Declar-
ation guidelines. The clinicopathological characteristics
and surgical data of the patients are shown in Table 1.
The indications for hepatic resection and the type of
operative procedures were usually determined based on
the patients’ liver function reserve, that is, according
to the results of the indocyanin green retention test at
15 minutes (ICGR15) [16]. Anatomical resection was
performed on patients in whom the ICGR15 was lower
than 25%. Anatomical resection was defined as a re-
section in which the lesions were completely removed
anatomically on the basis of Couinauds’ classification
(segmentectomy, sectionectomy, and hemihepatectomy
or more). Non-anatomical partial but complete resec-
tion was achieved in other cases. In all patients, sur-
gery was performed at R0 or R1. When R0 and R1
resections were performed, the resection surfaces were
found to be histologically or macroscopically free of
HCC, respectively. Follow-up studies after liver resec-
tion were conducted at three-month intervals, which
included physical, serological (liver function test, serum
alpha-fetoprotein (AFP) level, and serum protein in-
duced by vitamin K absence-II (PIVKA-II)), and radio-
logical examinations (ultrasound sonography (US) and
contrast-enhanced computed tomography (CT) scan or
contrast-enhanced magnetic resonance imaging (MRI)).
Recurrence was diagnosed on the basis of the results of
contrast-enhanced CT and elevation of serum levels of
AFP and/or PIVKA-II. Extrahepatic metastasis (lung,
lymph node, adrenal gland, brain and bone) was diag-
nosed by contrast-enhanced chest and abdominal CT,
contrast-enhanced head MRI and bone scintigram. The
median follow-up period was 111 months (range, 5 to
249 months).
Statistical analysis
Continuous variables were expressed as the means ±
standard deviation and compared using the χ2 test for cat-
egorical variables. Overall survival (OS) and recurrence-
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Figure 1 Overall survival curves of the younger and older
patient groups after first hepatectomy.
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portional hazards model was used for multivariate analysis.
Significance was defined as a P-value of <0.05. Statistical
analyses were performed using Stat View 5.0 for Windows
(SAS Institute, Cary, NC, USA).
Results
Clinicopathological characteristics and operative variables
Patient factors
The ratio of males to females (24:7) in the younger pa-
tient group was not significantly different from that of
the older patient group. Patients with HBV markers
accounted for most of the virus-associated cases: HBs-
antigen (HBs-Ag)-positive, 26/31 (total number in the
younger group) vs. 321/780 (total number in the older
group); 84% vs. 41%; P <0.0001. Patients who were hepa-
titis C virus (HCV)-antibody (HCV-Ab)-positive were sig-
nificantly fewer in number, that is, 1/31 vs. 310/780 (3% vs.
40%; P <0.0001) in the younger group. Although serum al-
bumin and total bilirubin levels were not significantly dif-
ferent between the groups, patients with ICGR15 ≥15 were
3/31 vs. 360/780 (10% vs. 46%; P = 0.0001).
Tumor factors
The younger group had significantly higher AFP levels
compared to the older group (P = 0.0026). Although the
number of tumors did not differ significantly between
the younger and older patients, there were significantly
more cases with a maximum tumor size of ≥5 cm in the
younger group (P = 0.0072). The mean maximum tumor
diameter in the younger group in this study was 8.6 ±
7.3 cm. Neither macroscopic type nor extrahepatic me-
tastasis was significantly different between the groups.
Operative variables
The rate of anatomical resections in the younger patients
was significantly higher than that in the older patients.
Pathological factors
There were significant differences between groups in
terms of microscopic tumor thrombus in the portal vein
(P = 0.0026) and microscopic intrahepatic metastasis
(P = 0.0413) (Table 1).
Causes of death and recurrence
Among the total 811 patients, 390 (48.1%) died. The
mortality rates were 17/31 (54.8%) in the younger pa-
tient group and 373/780 (47.8%) in the older patient
group. The causes of death, which did not differ signifi-
cantly between groups, were as follows: HCC recurrence
(n = 301; 77.2%; 16 in the younger patients vs. 285 in
the older patients), liver failure (n = 36; 9.2%; 0 in the
younger vs. 36 in the older patients), and other causes
(n = 53; 13.6%; 1 in the younger vs. 52 in the olderpatients). In addition, two patients in the older group died
of operative complications prior to 1995. No patients in
the younger group died of operative complications.
In the younger group, 22 patients experienced a recur-
rence (71.0%). There were 17 (77.3%) liver tumor recur-
rences, with a median recurrence time of six months (1 to
27). Lung metastases occurred in 11 (50.0%) cases, with a
median recurrence time of 12 months (1 to 42); bone me-
tastases in 7 (31.8%) cases, with a median recurrence time
of 23 months (6 to 60); brain metastases in 6 (27.3%) cases,
with a median recurrence time of 20 months (10 to 61);
lymph node metastases in 3 (13.6%) cases, with a median
recurrence time of 12 months (12 to 56); and adrenal gland
metastases in 3 (13.6%) cases, with a median recurrence
time of 10 months (5 to 50).
Cumulative rates of patient survival and recurrence-free
survival
The five-year OS rate of all 811 patients was 57.1%.
The five-year OS rate and median survival time (MST)
of the younger group were 49.6% and 40 months, re-
spectively, whereas those of the older group were 57.7%
and 79 months, respectively (Figure 1). The median
RFS time of all 811 patients was 23 months, while that
of the younger patients was 6 months, and that of the
older patients was 25 months (Figure 2). Neither OS
nor RFS were significantly different between the youn-
ger and older groups, although recurrence tended to
occur earlier in the younger patients.
Factors related to long-term survival and disease-free
survival after primary hepatectomy in the younger
patient group
Table 2 shows those factors that were found by univari-
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Figure 2 Recurrence-free survival curves of the younger and
older patient groups after first hepatectomy.
Table 2 Univariate analyses of prognostic factors of survival




Sex: Male NS NS
HBs-Ag positive NS NS
HCV-Ab positive 0.0172 NS
Biochemical Factors
Albumin <4.0 g/l 0.0088 NS
Total bilirubin ≥0.8 mg/dl NS Ns
ICGR15 ≥15 NS NS
AFP ≥200 ng/ml NS NS
Tumor Factors
Number of tumors: multiple NS 0.0199
Maximum size of tumor: ≥5 cm 0.0034 0.0006
Macroscopic classification: except for
simple nodular type
NS NS
Distant metastasis positive NS -
Surgical Factors
Non-anatomical resection NS NS
Histological Factors
Differentiation: poor NS 0.0395
vp2, 3, 4 0.0108 0.0020
im 0.0058 0.0053
cirrhosis 0.0446 NS
AFP, alpha-fetoprotein; HBs-Ag, HBs-antigen; HCV-Ab, HCV-antibody; ICGR15,
indocyanin green retention rate at 15 minutes; im, microscopic intrahepatic
metastasis; NS, non-significant; vp2, tumor thrombus in the second branches
of the portal vein; vp3, tumor thrombus in the first branch of the portal vein;
vp4, tumor thrombus extension to the trunk or the opposite side branch of
the portal vein.
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nificantly related to being HCV-Ab-positive, having a
serum albumin level of <4.0 g/l and a maximum tumor
size of ≥5 cm, the presence of tumor thrombus in the
second and first branches and trunk or opposite side
branch of the portal vein (vp2, 3, 4), microscopic
intrahepatic metastasis, and histological liver cirrhosis of
non-cancerous liver.
Univariate analysis showed that RFS was significantly re-
lated to multiple tumors, maximum tumor size of ≥5 cm,
poor differentiation, the presence of tumor thrombus
above vp2 and microscopic intrahepatic metastasis. Multi-
variate analysis showed HCV-Ab-positive status and serum
albumin levels of <4.0 g/l to be independent predictive fac-
tors for OS, and multiple tumors and vp2, 3, 4 were inde-
pendent predictive factors for RFS in the younger group of
patients (Tables 3 and 4).
Discussion
In this study, the younger patients with HCC who
underwent hepatectomy were more likely than the older
patients to be HBV-positive, to have large tumors with
portal invasion and to have high AFP, although they also
retained better liver function than the older patients.
Despite the significant difference in tumor progression,
neither OS nor RFS were significantly different between
the two groups, although recurrence tended to occur
earlier in the younger patients. Multivariate analysis
showed HCV-Ab-positive status and serum albumin
levels of <4.0 g/l to be independent predictive factors for
OS, and multiple tumors and vp2, 3, 4 were independent
predictive factors for RFS in the younger patients.
Therefore, young patients with hepatocellular carcinoma
should be aggressively treated with hepatectomy due to
their good pre-surgical liver function.
In the younger group of patients, HCV-Ab-positive
status and low serum albumin levels were the liver-
function-related factors that were found to be signifi-
cantly unfavorable in terms of OS, while multiple tumorsTable 3 Multivariate analyses of prognostic factors of
survival in the younger group
Risk factor P-value Hazard
ratio
95% CI
HCV-Ab positive 0.0196 59.816 1.927 to 1856.714
Albumin <4.0 g/l 0.0296 6.665 1.207 to 36.813
Maximum size of tumor: ≥5 cm NS 0.381 0.025 to 5.697
vp2, 3, 4 NS 2.313 0.420 to 12.738
im NS 14.563 0.951 to 222.939
cirrhosis NS 1.037 0.149 to 7.200
CI, confidence interval; HCV-Ab, HCV-antibody, im, microscopic intrahepatic
metastasis; NS, non-signficant; vp2, tumor thrombus in the second branches of the
portal vein; vp3, tumor rhombus in the first branch of the portal vein; vp4, tumor
thrombus extension to the trunk or the opposite side branch of the portal vein.
Table 4 Multivariate analyses of prognostic factors of
recurrence in the younger group
Risk factor P-value Hazard
ratio
95% CI
Number of tumor: multiple 0.0415 51.312 1.163 to 2264.565
Maximum size of tumor: ≥5 cm NS 3.210 0.353 to 29.152
Differentiation: poor NS 2.796 0.450 to 17.043
vp2, 3, 4 0.0253 13.517 1.380 to 132.442
im NS 0.137 0.005 to 3.541
CI, confidence interval; im, microscopic intrahepatic metastasis; NS, non-significant;
vp2, tumor thrombus in the second branches of the portal vein; vp3, tumor
thrombus in the first branch of the portal vein; vp4, tumor thrombus extension to
the trunk or the opposite side branch of the portal vein.
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significantly unfavorable in terms of RFS; moreover,
these findings were obtained by both univariate and
multivariate analyses. Although most of the younger pa-
tients had advanced tumors, no differences were found
between the younger and older patients in terms of OS.
These results indicate that aggressive and curative liver
resection should be performed for young patients with
HCC, because most young patients retain good pre-
surgical liver function.
The definition of who should be classified as a “young
patient” with HCC remains controversial. In the litera-
ture, the definition of a young patient with HCC has
tended to be a patient aged 40 years or younger
[4,8,10-12,14]. Cases of HCC in such patients are com-
paratively rare, for example, HCC occurs in only 0.6 to
2.7% of this age group in Japanese reports [12-14]. In
other countries, the reported rates of HCC in this age
range are as follows: 8.6% (40 years and younger) in
Singapore [11], 10.9% (under 40 years) in Taiwan [8] and
6.5% (40 years and younger) in Hong Kong [4]. Thus most
of the existing reports have been from Asia, and they show
a difference in frequency among regions. There appear to
be many young patients in Asia with HCC who are HBV-
positive; HBV is an underlying disease of HCC in young
patients, and many carriers live in Asia [17].
Many young patients with HCC have HBs-Ag, that is,
up to 71.4 to 100% [3-5,7-11,14]. Meanwhile, cases of
HCV-Ab-positivity plus HCC among younger patients
are reported at rates of 0 to 10% [4,5,7-10,12,14], which
is much lower than the range for older patients. Rates of
Child-Pugh A are 69.1 to 92.3% among younger patients
[4-6,8-12], which is higher than the range in older pa-
tients. It has been reported that histological hepatitis or
cirrhosis of non-cancerous liver is significantly less com-
mon in younger hepatectomy patients than in older hep-
atectomy patients among cases with HCC [3,4,12].
Though HCC is generally found by medical examination
or follow-up of liver function, in most young patients,
HCC is found by symptoms such as pain and/orpalpation of an abdominal mass [11,14,18,19]. Accord-
ingly, members of the younger patient group in this
study had larger tumors than the older patient group.
This study revealed that the rate of cases related to HBV
was 93.5%, and the rate of HBs-Ag-positive cases was
87.0%. The MST of the younger group was 40 months,
and the five-year OS rate was 49.6%. These results did not
differ significantly from the previously reported MST and
five-year OS rates of 27.8 to 52.5 months and 30.5 to
54.8%, respectively, among cases of liver resection for HCC
across all ages [20,21]. Therefore, it appears likely that
aggressive and curative liver resection contributes to
prolonged prognosis.
In regard to tumor factors, several studies have
reported that more young than old patients have
high AFP levels, that is, the rates of cases in which
AFP is equal to or exceeds a value of 400 ng/ml
range from 52.6 to 82.0% [3,7,9-11,14], and rates for
an AFP of ≥10,000 ng/ml range from 31.6 to 60.0%
[3,10,11,14]. In addition, younger patients tend to
have larger tumors than older patients, with the
maximum diameter of tumors being 6.9 to 12.7 cm
in younger patients [3,4,7,10,12,14]. Cases showing
portal invasion count for 45.0 to 100% [10-12,14] of
younger HCC patients. In the present study, the
younger patient group had higher AFP levels and lar-
ger tumors, was more likely to have portal invasion
and showed better liver function than the older
group, as has been reported elsewhere [3,7,10-12,14].
It has also been reported that cases with high AFP
levels have a poor prognosis due to a correlation be-
tween tumor size and AFP [22].
As regards prognostic factors, Chen et al. reported
that hepatectomy was a significant favorable prognostic
factor among HCC patients aged 40 years and younger
[8]. As regards other prognostic factors, AFP [8,11], por-
tal invasion [8,11] and reserved liver function [8,11,12]
have been reported, although these remain controversial.
In this study, prognostic factors related to OS were
HCV-Ab-positive status and low serum albumin levels,
and prognostic factors related to RFS were the number
of tumors and vp2, 3, 4. It has been suggested that liver
function preservation primarily influences survival, and
tumor factors influence recurrence. Furthermore, while
the time to recurrence in the younger patients was
shorter than that in the older patients, the RFS of the
younger group tended to overtake that of the older
group in the long term. The recurrence rate was 71%,
and the site of recurrence was almost always the liver.
This rate was comparable to those of other reports,
which ranged from 60.2 to 78.2% across all ages [20].
The results to date suggest that aggressive treatments,
including re-hepatectomy for recurrence, contribute to
an improvement in the long-term prognosis.
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take care to perform aggressive resections, and should
also make note of cases with a background of potentially
liver-affecting hepatitis B. Chuma et al. reported that the
quantity of HBV-DNA and non-treatment for HBV were
risk factors for a recurrence of HCC [23]. Li et al.
reported that one-year and two-year RFS rates were
23.3% vs. 8.3%, and 2.3% vs. 0%, respectively, in a treat-
ment group receiving lamivudine for HCC due to con-
current hepatitis B vs. a control group [24]. Therefore,
viral treatments in combination with cancer treatments,
including resection, are important to consider.
There have been few reports on liver transplantation
for young patients with HCC. The reason for this lack of
information is likely to be that younger patients have
relatively larger tumors and, therefore, they tend to have
tumors exceeding the Milan criteria. Ismail et al.
reported that the outcomes of liver transplantation were
better than those of liver resection among patients
with HCC who were aged 2 to 27 years, namely, the
OS rates were 72% vs. 40%, and the RFS rates were
91% vs. 30% [25]. It was also reported that primary
liver transplantation for children with HCC without
extrahepatic lesions has a good outcome, even if the
tumors exceed the Milan criteria [26]. An accumula-
tion of future cases is expected.
As noted above, many young HCC patients present
with advanced tumors and unfavorable prognostic fac-
tors. In a study on 16 patients who received liver trans-
plantation for HCC and who had low differentiation and
vascular invasion beyond the Milan criteria, Saab et al.
reported that those receiving sorafenib (n = 8) had one-
year OS rates and RFS rates of 87.5% and 85.7%, versus
62.5% and 57.1% for the control group (n = 8) [27]. It is
expected that supportive treatment with molecular tar-
get medicine after liver resection or transplantation
could contribute to a prolonged prognosis.Conclusions
In our younger patients with HCC, survival appeared to
be mainly affected by liver function while recurrence
was mainly affected by tumor factors. Young patients
with HCC should be offered aggressive hepatectomy due
to their relatively preserved liver function.Abbreviations
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